(Q36780383)

English

Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization

scientific article published on September 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

16 August 2017

Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization (English)

1 reference

Europe PubMed Central

16 August 2017

2

object named as

Maria Deak

0 references

object named as

Nicolas Dzamko

1

0 references

Alan R. Prescott

object named as

Alan R Prescott

5

0 references

object named as

Dario R Alessi

6

0 references

Alastair D Reith

4

object named as

Alastair D Reith

1 reference

Europe PubMed Central

16 August 2017

author name string

Faycal Hentati

3

1 reference

Europe PubMed Central

16 August 2017

R Jeremy Nichols

7

1 reference

Europe PubMed Central

16 August 2017

language of work or name

0 references

publication date

1 September 2010

1 reference

Europe PubMed Central

16 August 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

Biochemical Journal

1 reference

Europe PubMed Central

16 August 2017

430

1 reference

Europe PubMed Central

16 August 2017

405-413

1 reference

Europe PubMed Central

16 August 2017

3

1 reference

Europe PubMed Central

16 August 2017

copyright license

Creative Commons Attribution 3.0 Unported

25 July 2019

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631100

29 September 2017

Identification of the autophosphorylation sites of LRRK2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631100

29 September 2017

Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631100

29 September 2017

The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631100

29 September 2017

Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631100

29 September 2017

LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631100

29 September 2017

Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631100

29 September 2017

Solid tumor proteome and phosphoproteome analysis by high resolution mass spectrometry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631100

29 September 2017

Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631100

29 September 2017

Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631100

29 September 2017

LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631100

29 September 2017

Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631100

29 September 2017

The selectivity of protein kinase inhibitors: a further update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631100

29 September 2017

LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631100

29 September 2017

Transfection of mammalian cells using linear polyethylenimine is a simple and effective means of producing recombinant adeno-associated virus vectors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631100

29 September 2017

Kinase activity is required for the toxic effects of mutant LRRK2/dardarin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631100

29 September 2017

Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631100

29 September 2017

Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631100

29 September 2017

The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631100

29 September 2017

Phosphopeptide analysis reveals two discrete clusters of phosphorylation in the N-terminus and the Roc domain of the Parkinson-disease associated protein kinase LRRK2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631100

5 September 2018

Investigation of leucine-rich repeat kinase 2 : enzymological properties and novel assays.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631100

5 September 2018

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100784

21 January 2018

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100784

21 January 2018

Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1.

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100784

21 January 2018

Characterization of a protein kinase B inhibitor in vitro and in insulin-treated liver cells

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100784

21 January 2018

Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100784

21 January 2018

Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100784

21 January 2018

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100784

21 January 2018

The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901.

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100784

21 January 2018

BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100784

21 January 2018

Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100784

21 January 2018

SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100784

21 January 2018

Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase.

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100784

21 January 2018

SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100784

21 January 2018

BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100784

21 January 2018

Novel IKK inhibitors: beta-carbolines

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100784

21 January 2018

Inhibition of Tpl2 kinase and TNFalpha production with quinoline-3-carbonitriles for the treatment of rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100784

21 January 2018

Identification of RIP1 kinase as a specific cellular target of necrostatins

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100784

21 January 2018

The protein kinase A inhibitor H89 acts on cell morphology by inhibiting Rho kinase

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100784

21 January 2018

A novel conformationally restricted protein kinase C inhibitor, Ro 31-8425, inhibits human neutrophil superoxide generation by soluble, particulate and post-receptor stimuli.

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100784

21 January 2018

Rottlerin, a novel protein kinase inhibitor

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100784

21 January 2018

A single amino acid difference between alpha and beta Ca2+/calmodulin-dependent protein kinase kinase dictates sensitivity to the specific inhibitor, STO-609.

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100784

21 January 2018

Role of AMP-activated protein kinase in mechanism of metformin action

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100784

21 January 2018

Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100784

21 January 2018

Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100784

21 January 2018

The Src family tyrosine kinase is involved in Rho-dependent activation of c-Jun N-terminal kinase by Galpha12.

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100784

21 January 2018

Specific inhibition of cyclin-dependent kinases and cell proliferation by harmine

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100784

21 January 2018

Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100784

21 January 2018

SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100784

21 January 2018

VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100784

21 January 2018

Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100784

21 January 2018

Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100784

21 January 2018

BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100784

21 January 2018

EGF induced SOS phosphorylation in PC12 cells involves P90 RSK-2

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100784

21 January 2018

The threonine residues in MAP kinase kinase 1 phosphorylated by MAP kinase in vitro are also phosphorylated in nerve growth factor-stimulated rat phaeochromocytoma (PC12) cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/20659021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phosphorylation-dependent interactions between enzymes of plant metabolism and 14-3-3 proteins

1 reference

https://pubmed.ncbi.nlm.nih.gov/20659021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development of dihydropyridone indazole amides as selective Rho-kinase inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/20659021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1042/BJ20100784

1 reference

Europe PubMed Central

16 August 2017

1 reference

Europe PubMed Central

16 August 2017

1 reference

Europe PubMed Central

16 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36780383&oldid=2118670457"